OvaScience (OVAS) and Ampliphi Biosciences Corp (APHB) Financial Survey

OvaScience (NASDAQ: OVAS) and Ampliphi Biosciences Corp (NYSE:APHB) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitabiliy, institutional ownership, risk and analyst recommendations.

Earnings & Valuation

This table compares OvaScience and Ampliphi Biosciences Corp’s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	EBITDA	Earnings Per Share	Price/Earnings Ratio
OvaScience	$569,999.00	95.10	-$64.78 million	($2.22)	-0.68
Ampliphi Biosciences Corp	$182,999.00	38.93	-$12.29 million	N/A	N/A

Ampliphi Biosciences Corp has higher revenue, but lower earnings than OvaScience.

Profitability

This table compares OvaScience and Ampliphi Biosciences Corp’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OvaScience	-23,642.86%	-58.88%	-52.21%
Ampliphi Biosciences Corp	-11,193.10%	-159.06%	-80.13%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for OvaScience and Ampliphi Biosciences Corp, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OvaScience	1	3	1	0	2.00
Ampliphi Biosciences Corp	0	0	1	0	3.00

OvaScience currently has a consensus price target of $8.00, indicating a potential upside of 426.32%. Ampliphi Biosciences Corp has a consensus price target of $10.00, indicating a potential upside of 830.23%. Given Ampliphi Biosciences Corp’s stronger consensus rating and higher probable upside, analysts clearly believe Ampliphi Biosciences Corp is more favorable than OvaScience.

Insider & Institutional Ownership

63.7% of OvaScience shares are held by institutional investors. 12.6% of OvaScience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

OvaScience beats Ampliphi Biosciences Corp on 6 of the 10 factors compared between the two stocks.

About OvaScience

OvaScience, Inc. is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue. The Company’s AUGMENT treatment is designed to improve egg health by supplementing a mitochondrial deficiency. With the AUGMENT treatment, energy-producing mitochondria from a patient’s own EggPC cells are added to the patient’s mature eggs during the in vitro fertilization process to supplement the existing mitochondria. Its OvaPrime treatment is a fertility treatment designed to replenish a woman’s ovary by increasing her egg reserve using her own EggPC cells. Its OvaTure treatment is a fertility treatment that seeks to create mature fertilizable eggs in vitro from a woman’s own EggPC cells without the need for hormone hyperstimulation.

About Ampliphi Biosciences Corp

AmpliPhi Biosciences Corporation is a biotechnology company. The Company is focused on the discovery, development and commercialization of phage therapeutics. The Company is engaged in identifying, characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology, synthetic biology and manufacturing, to develop second-generation bacteriophage products. The Company is engaged in developing these phage product candidates using a discovery and development platform, which is designed for identification, characterization and manufacturing of multiple phage therapies. Each product candidate combines several chosen phages, which target a specific disease-causing bacterial pathogen, such as staphylococcus aureus (S. aureus), Pseudomonas aeruginosa (P. aeruginosa) and clostridium difficile (C. difficile). Its product candidates include AB-SA01, AB-PA01 and AB-CD01.